Bioenvision's (BIOV) Clofarabine Data Presented At Leading Hematology Congress; Durable Responses Reported At Leukemia 2004 Houston, Texas 
10/19/2005 5:11:49 PM

Bioenvision (NASDAQ:BIVN) announced today that, at the Leukemia 2004 Meeting in Houston, Texas, Professor Alan Burnett of the UK National Cancer Research Institute, Hematological Oncology Study Group, presented an update on emerging data from a study of clofarabine as first-line monotherapy in older adult patients with AML, who were considered unsuitable for intensive chemotherapy. Interim data, previously presented at the European Haematology Association meeting in June 2004 showed a complete response rate of 64% in this group of patients. This response rate was achieved after just one course of clofarabine monotherapy. So significant was this data that the study closed early to allow the company-sponsored registration trial to commence enrolment. According to the data included in the Medical Research Council (MRC) U.K. database, current best practice in this group of patients achieves a response rate of 17%.